Vivani Medical Q1 net loss $6.0M, cash $31.0M; NPM-115 IND on track for H2 2024

Vivani Medical, Inc.

2025-Q1 EPS reported -$0.12

Net loss of $6.0M in Q1 2024 vs $6.3M in Q1 2023; cash $31.0M at March 31, 2024, up from $22.0M.
Completed $15M registered direct offering in March 2024, extending cash runway into H2 2025.
NPM-115 IND submission on track for H2 2024; first-in-human trial planned after regulatory clearance.
Positive preclinical data: NPM-115 showed ~20% weight loss in mice, comparable to semaglutide.
Appointed Daniel Bradbury to Board; he led Amylin's development of first once-weekly GLP-1 Bydureon.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vivani Medical, Inc. reported first quarter ended March 31, 2024 results: net income Net loss during the three months ended March 31, 2024 was $6.0 million.

Period: first quarter ended March 31, 2024
Net income: Net loss during the three months ended March 31, 2024 was $6.0 million
Result: reported results

Exact text from the filing

Net loss during the three months ended March 31, 2024 was $6.0 million

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Vivani Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001753926-24-000957

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.